Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Bone Marrow Transplant ; 52(11): 1526-1529, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28714945

ABSTRACT

We screened 136 patients with myelofibrosis and a median age of 58 years who underwent allogeneic stem cell transplantation (AHSCT) for molecular residual disease for JAKV617F (n=101), thrombopoietin receptor gene (MPL) (n=4) or calreticulin (CALR) (n=31) mutation in peripheral blood on day +100 and +180 after AHSCT. After a median follow-up of 78 months, the 5-year estimated overall survival was 60% (95% confidence interval (CI): 50-70%) and the cumulative incidence of relapse at 5 years was 26% (95% CI: 18-34%) for the entire study population. The percentage of molecular clearance on day 100 was higher in CALR-mutated patients (92%) in comparison with MPL- (75%) and JAKV617F-mutated patients (67%). Patients with detectable mutation at day +100 or at day +180 had a significant higher risk of clinical relapse at 5 years than molecular-negative patients (62% vs 10%, P<0.001) and 70% vs 10%, P<0.001, respectively) irrespectively of the underlying mutation. In a multivariate analysis, high-risk diseases status (hazard ratio (HR) 2.5; 95% CI: 1.18-5.25, P=0.016) and detectable MRD at day 180 (HR 8.36, 95% CI: 2.76-25.30, P<0.001) were significant factors for a higher risk of relapse.


Subject(s)
Calreticulin/genetics , Janus Kinase 2/genetics , Neoplasm, Residual/genetics , Pathology, Molecular/methods , Primary Myelofibrosis/diagnosis , Receptors, Thrombopoietin/genetics , Hematopoietic Stem Cell Transplantation/methods , Hematopoietic Stem Cell Transplantation/mortality , Humans , Middle Aged , Mutation , Neoplasm, Residual/diagnosis , Neoplasm, Residual/mortality , Primary Myelofibrosis/genetics , Primary Myelofibrosis/mortality , Recurrence , Survival Rate , Transplantation, Homologous
2.
Bone Marrow Transplant ; 51(9): 1223-7, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27088376

ABSTRACT

Allogeneic hematopoieteic stem cell transplantation (HSCT) is the only curative treatment for myelofibrosis (MF), but it is still associated with significant risks and complications. One of these complications is poor graft function, but incidence and risk factors have not been studied yet. We retrospectively studied a cohort of 100 patients with primary MF or post-ET/PV MF who received a reduced-intensity HSCT in our center. The cumulative incidence of primary leukocyte engraftment was 98%. The cumulative incidence of poor graft function was 17% and all of the cases occurred before day 100 after HSCT at a median of 49 days (range 24-99 days). In the univariate analysis, age as continuous parameter (P=0.05; hazard ratio 1042) and persistence of significant splenomegaly (defined as palpable splenomegaly of ⩾10 cm under costal margin) at d+30 after HSCT (33% vs 12%; P=0.05) showed an increased cumulative incidence of poor graft function. In conclusion, the incidence of poor graft function after HSCT for MF is rather high, but did not influence survival. Persistence of splenomegaly after transplantation is a significant factor for poor graft function in myelofibrosis patients. Whether therapeutic reduction of splenomegaly before HSCT would result in a lower incidence of poor graft function should be investigated in future studies.


Subject(s)
Allografts/physiopathology , Hematopoietic Stem Cell Transplantation/methods , Primary Myelofibrosis/therapy , Adult , Age Factors , Aged , Female , Humans , Incidence , Male , Middle Aged , Primary Myelofibrosis/complications , Retrospective Studies , Risk Factors , Splenomegaly , Transplantation Conditioning/methods
3.
Leukemia ; 29(11): 2126-33, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26293647

ABSTRACT

The aim of this work is to produce recommendations on the management of allogeneic stem cell transplantation (allo-SCT) in primary myelofibrosis (PMF). A comprehensive systematic review of articles released from 1999 to 2015 (January) was used as a source of scientific evidence. Recommendations were produced using a Delphi process involving a panel of 23 experts appointed by the European LeukemiaNet and European Blood and Marrow Transplantation Group. Key questions included patient selection, donor selection, pre-transplant management, conditioning regimen, post-transplant management, prevention and management of relapse after transplant. Patients with intermediate-2- or high-risk disease and age <70 years should be considered as candidates for allo-SCT. Patients with intermediate-1-risk disease and age <65 years should be considered as candidates if they present with either refractory, transfusion-dependent anemia, or a percentage of blasts in peripheral blood (PB) >2%, or adverse cytogenetics. Pre-transplant splenectomy should be decided on a case by case basis. Patients with intermediate-2- or high-risk disease lacking an human leukocyte antigen (HLA)-matched sibling or unrelated donor, should be enrolled in a protocol using HLA non-identical donors. PB was considered the most appropriate source of hematopoietic stem cells for HLA-matched sibling and unrelated donor transplants. The optimal intensity of the conditioning regimen still needs to be defined. Strategies such as discontinuation of immune-suppressive drugs, donor lymphocyte infusion or both were deemed appropriate to avoid clinical relapse. In conclusion, we provided consensus-based recommendations aimed to optimize allo-SCT in PMF. Unmet clinical needs were highlighted.


Subject(s)
Hematopoietic Stem Cell Transplantation , Primary Myelofibrosis/therapy , Donor Selection , Histocompatibility Testing , Humans , Primary Myelofibrosis/mortality , Transplantation Conditioning , Transplantation, Homologous
8.
Bone Marrow Transplant ; 49(1): 126-30, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24037022

ABSTRACT

To investigate the impact of anti-lymphocyte globulin (ATG-Fresenius) as part of the HLA-sibling transplantation, we evaluated 238 patients (median age 48 years) with different diagnoses (AML, ALL, CML and lymphoproliferative disorders). A total of 79 patients received ATG and 159 patients did not. In the ATG group, there were more HLA-mismatched donors (6% vs 1%, p=0.02), bad risk patients (70% vs 55%, P=0.04), reduced intensity conditioning (RIC) regimens (65% vs 34%, P=<0.001) and older patients (median age 51 vs 48 years, P=0.002). The median time to leukocyte engraftment was significantly faster in the non-ATG group (13 vs 15 days, P < 0.001). EBV reactivation was more often seen in the ATG group (9% vs 2%, P=0.05). Cumulative incidence of acute and chronic GVHD was less observed in the ATG group (27% vs 40%, P=0.004, and 33% vs 54%, P=0.002). The cumulative incidence rates of non-relapse mortality and of relapse at 5 years were 20 and 34%, respectively, for ATG and 34 and 29%, respectively, for non-ATG (P=0.06 and P=0.3). ATG can prevent GVHD without an obvious risk of relapse but should be confirmed in a randomized study.


Subject(s)
Antilymphocyte Serum/therapeutic use , Graft vs Host Disease/prevention & control , Hematologic Diseases/therapy , Lymphocyte Depletion , Peripheral Blood Stem Cell Transplantation , T-Lymphocytes/cytology , Adolescent , Adult , Aged , Child , Clinical Trials as Topic , Disease-Free Survival , Female , HLA Antigens/immunology , Humans , Incidence , Leukocytes/cytology , Male , Middle Aged , Recurrence , Retrospective Studies , Risk , Siblings , Transplantation Conditioning , Transplantation, Homologous , Young Adult
9.
Bone Marrow Transplant ; 48(8): 1028-32, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23419435

ABSTRACT

In a retrospective study of 168 patients with AML in CR who underwent allo-SCT, we compare the impact of young unrelated donors (UD) vs older matched related donors (MRD) on 5-year OS (5-yr OS). Median follow-up was 59 months and median donor age was 39 years, which was used as cutoff for young vs older donors. Kaplan-Meier-estimated 5-yr OS was better with UD ≤39 years vs MRD >39 years (66% vs 34%, P=0.001). In multivariate analysis, only donor age and cytogenetic risk impacted 5-yr OS. Compared with UD ≤39 years, both MRD >39 years (relative risk (RR): 4.31, P=0.001) and UD >39 years (RR: 2.14, P=0.03) were associated with poorer 5-yr OS. Standard-risk cytogenetics was associated with better 5-yr OS compared with bad-risk cytogenetics, (RR: 0.53, P=0.02). Subgroup analyses of patients ≥50 years (n=76) revealed similar results, with 5-yr OS of 62% for UD ≤39 yrs and 26% for MRD >39 yrs (P=0.022). In patients undergoing allo-HSCT for AML, young UD may improve outcome as compared with older MRD.


Subject(s)
Donor Selection/methods , Hematopoietic Stem Cell Transplantation/methods , Leukemia, Myeloid, Acute/surgery , Living Donors , Adult , Age Factors , Donor Selection/standards , Female , Hematopoietic Stem Cell Transplantation/standards , Humans , Male , Remission Induction , Retrospective Studies , Survival Analysis , Treatment Outcome
10.
Leukemia ; 27(3): 604-9, 2013 Mar.
Article in English | MEDLINE | ID: mdl-22821073

ABSTRACT

We investigated whether a young human leukocyte antigen (HLA)-matched unrelated donor (MUD) should be preferred as donor to an HLA-identical sibling (MRD) for older patients with myelodysplastic syndrome (MDS) (≥ 50 years) who underwent allogeneic stem cell transplantation (AHSCT). Outcomes of 719 MDS patients with a median age of 58 years (range, 50-73 years) who received AHSCT from related (n=555) or unrelated (n=164) donors between 1999 and 2008 and reported to the European Group for Blood and Marrow Transplantation were analyzed. The median donor age of the MRD was 56 years (range: 35-78), in contrast to 34 years (range: 19-64) for the MUDs. Influence of donor's age on survival was not observed for MRD (hazard ratio (HR): 1.01 (95% confidence interval (CI): 0.99-1.02), P=0.2), but there was a significant impact of MUD's age on outcome (HR: 1.03 (95% CI: 1.01-1.06); P=0.02). Transplantation from younger MUDs (<30 years) had a significant improved 5-year overall survival in comparison with MRD and older MUDs (>30 years): 40% vs 33% vs 24% (P=0.04). In a multivariate analysis, AHSCT from young MUD (<30 years) remained a significant factor for improved survival in comparison with MRD (HR: 0.65 (95% CI: 0.45-0.95), P=0.03), which should be considered in donor selection for older patients.


Subject(s)
HLA Antigens/metabolism , Myelodysplastic Syndromes/mortality , Neoplasm Recurrence, Local/mortality , Stem Cell Transplantation , Adult , Aged , Donor Selection , Female , Follow-Up Studies , Humans , Male , Middle Aged , Myelodysplastic Syndromes/immunology , Myelodysplastic Syndromes/therapy , Neoplasm Recurrence, Local/immunology , Neoplasm Recurrence, Local/therapy , Prognosis , Siblings , Survival Rate , Transplantation, Homologous , Unrelated Donors , Young Adult
13.
Bone Marrow Transplant ; 45(9): 1404-7, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20062088

ABSTRACT

Monitoring of minimal residual disease (MRD) after allogeneic (allo)-SCT for myelofibrosis (MF) allows recognizing the depth of remission and thus guides application of appropriate therapeutic interventions. MPL W515L/K mutations, which are detected in 5-10% of JAK2V617F-negative patients, may be useful for this purpose. Using a highly sensitive quantitative PCR method, we tested 90 patients with MF who underwent allo-SCT for the presence of MPL W515L/K mutations. Two patients with primary MF were found to harbor MPLW515L while no patient was positive for MPLW515K mutation. Both patients were JAK2V617F negative and cleared the mutation rapidly after allo-SCT and remained negative for a median follow-up of 19 months. The results of molecular monitoring correlated well with other remission parameters such as normalization of peripheral blood counts and morphology and complete donor chimerism. We conclude that MPLW515L can be cleared after allo-SCT and hence may be used as an MRD marker in a proportion of JAK2V617F-negative MF patients.


Subject(s)
Genetic Testing/methods , Hematopoietic Stem Cell Transplantation , Primary Myelofibrosis/genetics , Primary Myelofibrosis/therapy , Receptors, Thrombopoietin/genetics , Aged , Female , Follow-Up Studies , Genetic Markers/genetics , Genetic Testing/standards , Humans , Janus Kinase 2/genetics , Neoplasm, Residual/genetics , Neoplasm, Residual/therapy , Reproducibility of Results , Retrospective Studies , Reverse Transcriptase Polymerase Chain Reaction , Transplantation, Homologous
SELECTION OF CITATIONS
SEARCH DETAIL
...